Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache
2024-515166-14-00Phase 3Authorised
- Sponsor
- Norwegian University of Science and Technology
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Cluster Headache (CH) comparing Botox with Placebo (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2024-515166-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515166-14-00.